Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05282771 · ClinicalTrials.gov registry record · Early Phase 1
A Study Comparing Halobetasol Propionate and Tazarotene Topical Lotion 0.01%/0.045% to Duobrii® Lotion (Halobetasol Propionate and Tazarotene Lotion), 0.01%/0.045% (Reference Listed Drug) in the Treatment of Moderate to Severe Plaque Psoriasis.
A Early Phase 1 study, sponsored by Sun Pharmaceutical Industries.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 402
- Enrollment target
NCT05282771: Completed Early Phase 1 study, sponsored by Sun Pharmaceutical Industries.
NCT05282771 is a Early Phase 1 study that has completed, run by Sun Pharmaceutical Industries. The registered enrollment target is 402 participants, above the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (658% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05282771, a Early Phase 1 study, has completed, sponsored by Sun Pharmaceutical Industries.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 402 participants
- Enrollment target
Study Summary
To evaluate the therapeutic equivalence and safety of halobetasol propionate and tazarotene topical lotion 0.01%/0.045% (Taro Pharmaceuticals U.S.A., Inc.) and Duobrii® Lotion (halobetasol and tazarotene lotion), 0.01%/0.045% (Reference Listed Drug) in the treatment of moderate to severe plaque psoriasis.
Interventions
- DRUG Placebo
- DRUG Halobetasol Propionate and Tazarotene Lotion 0.01%/0.045%
- DRUG Duobrii® Lotion (Halobetasol propionate and tazarotene lotion), 0.01%/0.045%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 402 participants |
| Start Date | 2021-04-16 |
| Est. Completion | 2022-02-10 |
| Phase | Early Phase 1 |
What the finished NCT05282771 record still lists
NCT05282771 is an interventional study that assigns participants to a tested intervention. The registered 402 participants enrollment target is mid-sized for trials with a published cap, above the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (658% higher).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT05282771 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05282771 about?
NCT05282771 is a clinical study titled "A Study Comparing Halobetasol Propionate and Tazarotene Topical Lotion 0.01%/0.045% to Duobrii® Lotion (Halobetasol Propionate and Tazarotene Lotion), 0.01%/0.045% (Reference Listed Drug) in the Treatment of Moderate to Severe Plaque Psoriasis.". To evaluate the therapeutic equivalence and safety of halobetasol propionate and tazarotene topical lotion 0.01%/0.045% (Taro Pharmaceuticals U.S.A., Inc.) and Duobrii® Lotion (halobetasol and tazarotene lotion), 0.01%/0.045% (Reference Listed Drug) in the treatment of moderate to severe plaque psor...
What is the current status of trial NCT05282771?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 402 participants. The study started on 2021-04-16. Estimated completion is 2022-02-10.
What interventions are being tested in trial NCT05282771?
The interventions under investigation include: Placebo (DRUG), Halobetasol Propionate and Tazarotene Lotion 0.01%/0.045% (DRUG), Duobrii® Lotion (Halobetasol propionate and tazarotene lotion), 0.01%/0.045% (DRUG).
Who is sponsoring clinical trial NCT05282771?
This trial is sponsored by Sun Pharmaceutical Industries, which has 48 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05282771's enrollment target sits among peer trials
402 25th of 2000 higher than 1,976 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04464226 · 402 participants · Phase 3
Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer
- NCT05183763 · 402 participants · NA
Medication Adherence Program
- NCT06748222 · 402 participants · Phase 3
E-Mindfulness Approaches for Living After Breast Cancer
- NCT06896474 · 402 participants · NA
SDM POSSIBLE: A Breast Cancer Treatment Decision Aid for Women 70+ With Low-Risk Stage I Breast Cancers
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI